Saroglitazar at the Crossroads of Metabolic and Neurodegenerative Disease: A Critical Review of the Hepato-Neuro Axis and Translational Horizons
Neurochemical Research · 2025
DOI: 10.1007/s11064-025-04607-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurochemical Research, 2025. Verfasst von Himanshu Kumar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Laureate Institute of Pharmacy, Kathog, Distt. Kangra, 176031, Himachal Pradesh, India. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Non-alcoholic Fatty Liver Disease, Phenylpropionates, Liver. Die Arbeit nennt 102 Literaturangaben.
Abstract (Originalsprache)
Non-Alcoholic Fatty Liver Disease (NAFLD) is increasingly recognized as a systemic disorder with implications far beyond the liver, notably in the progression of cognitive decline and neurodegenerative disorders such as Alzheimer's disease (AD) and traumatic brain injury (TBI). At the center of this liver-brain axis lies Saroglitazar (SGZ), a dual PPAR-α/γ agonist initially developed for diabetic dyslipidemia. Emerging evidence suggests that SGZ exerts neuroprotective effects via multiple molecular mechanisms, including modulation of oxidative stress, inflammation, and mitochondrial integrity. This review critically evaluates the mechanistic intersections of SGZ's hepatic and neural actions and proposes a unified framework for its therapeutic impact. We contextualize SGZ's role alongside alternative therapies, explore its translational readiness, and propose testable hypotheses to guide future research. While preclinical evidence is promising, robust human studies are essential to validate SGZ's potential in mitigating NAFLD-associated cognitive impairment. This article aims to advance a novel conceptual synthesis and call for integrative strategies targeting the hepato-neuro axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Laureate Institute of Pharmacy, Kathog, Distt. Kangra, 176031, Himachal Pradesh, India.
- Department of Pharmacology, Laureate Institute of Pharmacy, Kathog, Distt. Kangra, 176031, Himachal Pradesh, India. shiv.kushawaha@gmail.com.
- Department of Pharmacology, Laureate Institute of Pharmacy, H.P, Kathog, District Kangra, 176031, India. shiv.kushawaha@gmail.com.
- Department of Pharmaceutics, Laureate Institute of Pharmacy, Kathog, Distt. Kangra, 176031, Himachal Pradesh, India.
- Department of Clinical Haemato-Oncology & Bone Marrow Transplantation, Christian Medical College & Hospital, Ludhiana, Punjab, India.
- Pharma Innovation Lab, Department of Pharmaceutical Sciences &Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, 151001, India.
Zitieren
APA
Kumar, H., Vashisht, K., Kushawaha, S. K., Bhatia, V., Ashawat, M. S., Arora, R., & Baldi, A. (2025). Saroglitazar at the Crossroads of Metabolic and Neurodegenerative Disease: A Critical Review of the Hepato-Neuro Axis and Translational Horizons. Neurochemical Research. https://doi.org/10.1007/s11064-025-04607-4
Vancouver
Kumar H, Vashisht K, Kushawaha SK, Bhatia V, Ashawat MS, Arora R, et al. Saroglitazar at the Crossroads of Metabolic and Neurodegenerative Disease: A Critical Review of the Hepato-Neuro Axis and Translational Horizons. Neurochemical Research. 2025. doi:10.1007/s11064-025-04607-4
BibTeX
@article{Kumar2025,
author = {Kumar, Himanshu and Vashisht, Kanika and Kushawaha, Shiv Kumar and Bhatia, Vandana and Ashawat, Mahendra Singh and Arora, Rimpi and Baldi, Ashish},
title = {Saroglitazar at the Crossroads of Metabolic and Neurodegenerative Disease: A Critical Review of the Hepato-Neuro Axis and Translational Horizons},
journal = {Neurochemical Research},
year = {2025},
doi = {10.1007/s11064-025-04607-4}
}
EUVIMED